SRRA - Sierra Oncology, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.4301
-0.0031 (-0.72%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.4332
Open0.4300
Bid0.0000 x 900
Ask0.4497 x 1200
Day's Range0.4210 - 0.4620
52 Week Range0.4000 - 2.0700
Volume387,713
Avg. Volume1,073,270
Market Cap32.123M
Beta (3Y Monthly)0.90
PE Ratio (TTM)N/A
EPS (TTM)-0.7370
Earnings DateNov 6, 2019 - Nov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.33
Trade prices are not sourced from all markets
  • PR Newswire15 days ago

    Sierra Oncology Reports Second Quarter 2019 Results

    - Sierra preparing to launch the MOMENTUM Phase 3 myelofibrosis clinical trial expected in Q4 2019 - - Exploring non-dilutive options to support future continued development of DDR portfolio - VANCOUVER ...

  • PR Newswire16 days ago

    Sierra Oncology to Present at the Wedbush PacGrow Healthcare Conference in New York

    VANCOUVER, Aug. 7, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company at 2:30 pm ET on Wednesday, August 14 at the Wedbush PacGrow Healthcare Conference being held in New York. A live audio webcast and archive of the presentation will be accessible through the Sierra Oncology website at www.sierraoncology.com. Sierra Oncology is a late stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology.

  • Did Sierra Oncology, Inc. (NASDAQ:SRRA) Insiders Buy Up More Shares?
    Simply Wall St.last month

    Did Sierra Oncology, Inc. (NASDAQ:SRRA) Insiders Buy Up More Shares?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • Hedge Funds Have Never Been More Bullish On Sierra Oncology, Inc. (SRRA)
    Insider Monkey2 months ago

    Hedge Funds Have Never Been More Bullish On Sierra Oncology, Inc. (SRRA)

    You probably know from experience that there is not as much information on small-cap companies as there is on large companies. Of course, this makes it really hard and difficult for individual investors to make proper and accurate analysis of certain small-cap companies. However, well-known and successful hedge fund managers like Jeff Ubben, George Soros […]

  • CNW Group2 months ago

    Sierra Oncology Launches Campaign Exploring Non-Dilutive Strategic Options to Support Development of its DDR Assets

    VANCOUVER , June 27, 2019 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced plans to prioritize its existing resources on the development of momelotinib, its differentiated Phase 3 drug candidate for the treatment of patients with myelofibrosis. Sierra also announced it has launched a campaign exploring non-dilutive strategic options to support the future continued development of its portfolio of potent and selective DDR (DNA Damage Response) assets, consisting of SRA737 (Chk1 inhibitor) and SRA141 (Cdc7 inhibitor). "We recently reported compelling proof-of-concept clinical efficacy data for SRA737 at the 2019 ASCO Annual Meeting, demonstrating that this drug candidate has notable anti-cancer activity in multiple indications and a defined clinical path forward towards potential initial registration for the treatment of anogenital cancer, an indication with considerable unmet need.

  • CNW Group3 months ago

    Sierra Announces Momelotinib Granted FDA Fast Track Designation

    Sierra Announces Momelotinib Granted FDA Fast Track Designation

  • CNW Group3 months ago

    Sierra Announces FDA Regulatory Clarity for Momelotinib & Design of the MOMENTUM Phase 3 Clinical Trial

    Sierra Announces FDA Regulatory Clarity for Momelotinib & Design of the MOMENTUM Phase 3 Clinical Trial

  • PR Newswire3 months ago

    Sierra Holds Analyst & Investor Event for SRA737

    VANCOUVER, June 3, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, is holding an analyst and investor event today featuring distinguished oncologists Professor Johann de Bono and Dr. Rebecca Kristeleit, to discuss clinical findings and possible next steps for its oral, highly selective Chk1 inhibitor, SRA737.

  • PR Newswire3 months ago

    Sierra Announces Promising Preliminary Efficacy in SRA737 Clinical Program & Outlines Potential Path to Registration

    - Sierra reports 30% response rate for SRA737+LDG in anogenital cancer - - Anti-cancer activity demonstrated across multiple indications and genetic contexts in preliminary Phase 1/2 data presentations ...

  • PR Newswire3 months ago

    Sierra Oncology to Present Momelotinib and SRA737 Overview at the Jefferies Global Healthcare Conference in New York

    VANCOUVER, May 28, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced that Dr. Nick Glover, President and Chief Executive Officer, will present an overview of the company and updates concerning its clinical stage drug candidates, momelotinib and SRA737, at 8:00 am ET on Wednesday, June 5 at the Jefferies Global Healthcare Conference being held in New York. A live audio webcast and archive of the presentation will be accessible through the Sierra Oncology website at www.sierraoncology.com. Sierra Oncology is a clinical stage drug development company advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology.

  • PR Newswire3 months ago

    Sierra to Present SRA737 Preliminary Clinical Data and Potential Next Steps at ASCO

    - SRA737 Phase 1/2 Monotherapy and SRA737+LDG (Low Dose Gemcitabine) trials selected for poster presentations on June 1 st - - Sierra to hold Analyst & Investor Event at 6:00 am CT on June 3 rd featuring ...

  • Associated Press4 months ago

    Sierra Oncology, Inc: 1Q Earnings Snapshot

    The Vancouver, British Columbia-based company said it had a loss of 17 cents per share. The company's shares closed at $1.49. A year ago, they were trading at $1.99. _____ This story was generated by Automated ...

  • PR Newswire4 months ago

    Sierra Oncology Reports First Quarter 2019 Results

    Momelotinib regulatory pathway clarity anticipated in Q2 2019 - - SRA737 Phase 1/2 preliminary clinical data anticipated at the 2019 ASCO Annual Meeting - VANCOUVER , May 8, 2019 /PRNewswire/ - Sierra ...

  • CNW Group4 months ago

    Sierra Oncology to Attend Two Investor Conferences in May

    VANCOUVER , May 6, 2019 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced that members of its senior management team will be attending the SunTrust Robinson Humphrey 5th Annual Life Sciences Conference in New York on May 8th , and the Oppenheimer Oncology Insight Summit in New York on May 16th . Sierra Oncology is a clinical stage drug development company advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology.